Literature DB >> 1384640

High prevalence of Clostridium difficile diarrhoea during intensive chemotherapy for disseminated germ cell cancer.

H Nielsen1, G Daugaard, M Tvede, B Bruun.   

Abstract

A prospective, consecutive study of the aetiology of treatment-associated diarrhoea was conducted in 25 patients with disseminated germ cell cancer treated with intensive chemotherapy. Clostridium difficile was isolated in 45% of the diarrhoea episodes, which makes this species the most important bacterial pathogen in the development of clinically significant diarrhoea in this group of immunocompromised patients.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1384640      PMCID： PMC1977424          DOI： 10.1038/bjc.1992.334

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  10 in total

1.  Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.

Authors:  M Wolf; K Havemann; R Holle; C Gropp; P Drings; K Hans; M Schroeder; M Heim; M Dommes; S Mende
Journal:  J Clin Oncol       Date:  1987-12       Impact factor: 44.544

2.  High-dose cisplatin and VP-16 with bleomycin, in the management of advanced metastatic germ cell tumors.

Authors:  G Daugaard; M Rŗth
Journal:  Eur J Cancer Clin Oncol       Date:  1986-04

3.  Relapsing pseudomembranous colitis associated with cancer chemotherapy.

Authors:  V Fainstein; G P Bodey; R Fekety
Journal:  J Infect Dis       Date:  1981-06       Impact factor: 5.226

4.  Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients.

Authors:  M Tvede; J Rask-Madsen
Journal:  Lancet       Date:  1989-05-27       Impact factor: 79.321

5.  Clostridium difficile. Colonization and toxin production in a cohort of patients with malignant hematologic disorders.

Authors:  J G Morris; W R Jarvis; O L Nunez-Montiel; M L Towns; F S Thompson; V R Dowell; E O Hill; W R Vogler; E F Winton; J M Hughes
Journal:  Arch Intern Med       Date:  1984-05

6.  Clostridium difficile colitis associated with the use of antineoplastic agents.

Authors:  S D Miller; H J Koornhof
Journal:  Eur J Clin Microbiol       Date:  1984-02       Impact factor: 3.267

Review 7.  Beta-lactam antibiotics and beta-lactamases: two sides of a continuing story.

Authors:  M H Richmond
Journal:  Rev Infect Dis       Date:  1979 Jan-Feb

8.  Clostridium difficile in haematological malignancy.

Authors:  A Rampling; R E Warren; P C Bevan; C E Hoggarth; D Swirsky; F G Hayhoe
Journal:  J Clin Pathol       Date:  1985-04       Impact factor: 3.411

9.  Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis.

Authors:  K H Kim; R Fekety; D H Batts; D Brown; M Cudmore; J Silva; D Waters
Journal:  J Infect Dis       Date:  1981-01       Impact factor: 5.226

10.  Clostridium difficile colitis associated with cancer chemotherapy.

Authors:  M A Cudmore; J Silva; R Fekety; M K Liepman; K H Kim
Journal:  Arch Intern Med       Date:  1982-02
  10 in total
  7 in total

1.  Risks factors and outcomes of Clostridium difficile infection in patients with cancer: a matched case-control study.

Authors:  Andrew I T Hebbard; Monica A Slavin; Caroline Reed; Jason A Trubiano; Benjamin W Teh; Gabrielle M Haeusler; Karin A Thursky; Leon J Worth
Journal:  Support Care Cancer       Date:  2017-02-02       Impact factor: 3.603

2.  Have enteric infections a role in 5-fluorouracil-associated diarrhea?

Authors:  S Cascinu; G Catalano
Journal:  Support Care Cancer       Date:  1995-09       Impact factor: 3.603

Review 3.  Role of the leukocyte response in normal and immunocompromised host after Clostridium difficile infection.

Authors:  Edwin Vargas; Senu Apewokin; Rajat Madan
Journal:  Anaerobe       Date:  2017-02-20       Impact factor: 3.331

4.  Clinical significance of Clostridium difficile and its toxins in faeces of immunocompromised children.

Authors:  M J Wolfhagen; K Meijer; A C Fluit; R Torensma; R A Bruinsma; A Fleer; J Verhoef
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

5.  Recurrent Pseudomembranous Colitis in an Ovarian Cancer Patient Undergoing Carboplatin Chemotherapy.

Authors:  Valerie A Allen; Kelly J Manahan; John P Geisler
Journal:  Case Rep Obstet Gynecol       Date:  2016-03-08

6.  Clostridium difficile fecal toxin level is associated with disease severity and prognosis.

Authors:  Nathaniel A Cohen; Tamar Miller; Wasef Na'aminh; Keren Hod; Amos Adler; Daniel Cohen; Hanan Guzner-Gur; Erwin Santo; Zamir Halpern; Yehuda Carmeli; Nitsan Maharshak
Journal:  United European Gastroenterol J       Date:  2017-12-21       Impact factor: 4.623

7.  Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patients.

Authors:  Thorsten Fuereder; Danjel Koni; Andreas Gleiss; Michael Kundi; Athanasios Makristathis; Christoph Zielinski; Christoph Steininger
Journal:  Sci Rep       Date:  2016-08-11       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.